NCT06387667 Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections
| NCT ID | NCT06387667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New Valley University |
| Condition | Immunocompromised ICU Patients With Respiratory Tract Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-12-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.
Eligibility Criteria
Inclusion Criteria: * All adult patients (aged \>18 years old) admitted to the Assiut University Hospital's intensive care units with pneumonia and hospitalized patients who developed hospital-acquired or ventilator-associated pneumonia who don't respond to antibiotics for 48 hours or with a CT finding suspected for fungal pneumonia. Patients included must have at least one of the following conditions as a contributor to immunocompromise: * Pre-existing lung disease: IPF, COPD, or sarcoidosis. * Immunosuppression: Neutropenia, on corticosteroids, or immunosuppressive drugs, inherited or acquired immunodeficiency. * Underlying comorbidities: (Diabetes Mellitus,Chronic kidney disease, Liver cirrhosis) * Malignancy (Hematological or solid) Exclusion Criteria: * Patients refused to contribute to the study. * Unsatisfactory sample.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06387667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Immunocompromised ICU Patients With Respiratory Tract Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06387667 currently recruiting?
Yes, NCT06387667 is actively recruiting participants. Contact the research team at asmaanady_1010@med.nvu.edu.eg for enrollment information.
Where is the NCT06387667 trial being conducted?
This trial is being conducted at Asyut, Egypt.
Who is sponsoring the NCT06387667 clinical trial?
NCT06387667 is sponsored by New Valley University. The trial plans to enroll 250 participants.